In these new clinical trials, 26 people aged between 18 and 55 will receive one dose of the ChAdOx1 biEBOV Ebola vaccine at the University of Oxford.2019: Deadly Ebola outbreak in DR Congo 'now a global emergency'
The vaccine is based on a weakened version of a common cold virus that has been genetically modified so it cannot replicate in humans.
If that's as successful as the Coronovirus ,keep helping Ebola victims
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: